期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 60
卷 60, 期 -, 页码 291-309出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010919-023429
关键词
cerebral edema; clinical trial; antiedema drug
资金
- National Institute of Neurological Disorders and Stroke (NINDS) [5R01NS061934]
- NINDS [R01NS060801, R01NS102589, R01NS105633, R01NS099209, U24NS107136, U24NS107215, U01NS106513, RO1NR018335]
- Biogen
- American Heart Association (AHA) [17CSA33550004]
- National Aeronautics and Space Administration [17-BPBA_2-0160]
- AHA [17CSA33550004]
- National Heart, Lung, and Blood Institute [R01HL082517]
Cerebral edema, a common and often fatal companion to most forms of acute central nervous system disease, has been recognized since the time of ancient Egypt. Unfortunately, our therapeutic armamentarium remains limited, in part due to historic limitations in our understanding of cerebral edema pathophysiology. Recent advancements have led to a number of clinical trials for novel therapeutics that could fundamentally alter the treatment of cerebral edema. In this review, we discuss these agents, their targets, and the data supporting their use, with a focus on agents that have progressed to clinical trials.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据